# LENZ catalysts: LENZ Therapeutics, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/lenz/catalysts

> LENZ Therapeutics, Inc. (LENZ) has no upcoming catalysts in this calendar. The latest recorded is the LENZ Therapeutics, Inc. earnings report, October 28, 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | LENZ Therapeutics, Inc. |
| Ticker | LENZ (Nasdaq) |
| SEC CIK | 1815776 |
| SIC | 2836 |
| SEC filings | https://sec-api.dev/companies/lenz |

## Cash runway

Cash $30.6M as of 2026-09-30; quarterly burn $22.3M; about 4.1 months of runway at that rate (XBRL company facts, accession 0001815776-26-000059).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Aug 2024 | [LNZ100 NDA/BLA submission](https://sec-api.dev/pdufa/lnz100) | LENZ |  | completed | "Based on the results of our Phase 3 CLARITY trials, we selected LNZ100 as our lead product candidate, for which we submitted an NDA to FDA in August 2024." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000059/lenz-20260930.htm)) |
| Oct 2024 | [LNZ100 NDA/BLA acceptance](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia, a condition | completed | "In October 2024, the Company announced that the FDA accepted the NDA for LNZ100 for the treatment of presbyopia." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm)) |
| October 27, 2024 | [JX07001 topline data readout](https://sec-api.dev/pdufa/jx07001) | LENZ | presbyopia in China | completed, positive | "On October 27, 2024, CORXEL and the Company announced positive topline data from the Phase 3 JX07001 clinical trial of VIZZ in patients with presbyopia in China." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000011/lenz-20251231.htm)) |
| March 19, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000017/a991q424pressrelease.htm)) |
| May 7, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000030/a991q125pressrelease.htm)) |
| July 30, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm)) |
| July 31, 2025 | [LNZ100 FDA approval](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia in adults | completed, approved | "•Announced FDA approval of VIZZ for the treatment of presbyopia on July 31, 2025 as the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia, a condition impacting approximately 128 million adults in the United States." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm)) |
| August 8, 2025 | [LNZ100 PDUFA date](https://sec-api.dev/pdufa/lnz100) | LENZ | presbyopia | completed, approved | "New Drug Application (NDA) for LNZ100 for treatment of presbyopia on track for PDUFA target action date of August 8, 2025" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000054/a991q225pressrelease.htm)) |
| November 5, 2025 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577625000069/a991q325pressrelease.htm)) |
| January 7, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000003/exhibit991-q425certainfina.htm)) |
| March 24, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000008/a991q425pressrelease.htm)) |
| May 11, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports First Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000035/a991q126pressrelease.htm)) |
| June 30, 2026 | [LENZ Therapeutics, Inc. FDA approval](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed, approved | "Through June 30, 2026, the Company has devoted substantially all of its efforts to product development, pre-commercial and commercial activities following the FDA approval of VIZZ in July 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000052/lenz-20260630.htm)) |
| August 11, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000051/a991q226pressrelease.htm)) |
| September 30, 2026 | [LENZ Therapeutics, Inc. FDA approval](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed, approved | "Through September 30, 2026, the Company has devoted substantially all of its efforts to product development, pre-commercial and commercial activities following the FDA approval of VIZZ in July 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000059/lenz-20260930.htm)) |
| October 28, 2026 | [LENZ Therapeutics, Inc. earnings report](https://sec-api.dev/companies/lenz/catalysts) | LENZ |  | completed | "LENZ Therapeutics Reports Third Quarter 2026 Financial Results, Announces Strategic Consumer Marketing Focused Reorganization and CEO Succession" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1815776/000181577626000056/a991q326pressrelease.htm)) |

## Drugs

- [JX07001](https://sec-api.dev/pdufa/jx07001): presbyopia in china
- [LNZ100](https://sec-api.dev/pdufa/lnz100): presbyopia in adults, presbyopia, presbyopia, a condition

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/lenz/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "LENZ catalysts: LENZ Therapeutics, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/lenz/catalysts

```bibtex
@misc{secapidev_companies_lenz_catalysts_20261116,
  title        = {LENZ catalysts: LENZ Therapeutics, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/lenz/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_lenz_catalysts_20261116","title":"LENZ catalysts: LENZ Therapeutics, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/lenz/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
